Glioblastoma Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

October 10 02:37 2023
Glioblastoma Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight’s, “Glioblastoma Pipeline Insight 2023” report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in the Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Glioblastoma Pipeline Report

  • DelveInsight’s Glioblastoma pipeline report depicts a robust space with 195+ active players working to develop 210+ pipeline therapies for Glioblastoma treatment.
  • The leading companies working in the Glioblastoma Market include Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
  • Promising Glioblastoma Pipeline Therapies in the various stages of development include PLX3397, Temozolomide, VXM01, Avelumab, Cilengitide, ACT001, and others.
  • September 2023: Laminar Pharmaceuticals announced a study of Phase 2 & 3 Clinical trials for LAM561 and TMZ. The proposed Phase IIB/III randomized, double-blind, placebo-controlled trial in subjects with newly diagnosed primary glioblastoma multiforme (ndGBM) aims to compare the efficacy and safety of LAM561 versus placebo, given with standard of care (SoC) therapy of radiation therapy plus temozolomide (TMZ), followed by an adjuvant treatment of 6 month period of TMZ and then LAM561 or placebo in monotherapy.
  • September 2023: Cantex Pharmaceuticals announced a study of Phase 1 & 2 Clinical trials for Azeliragon 5 mg. This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients with newly diagnosed glioblastoma receiving concurrent radiation and temozolomide.

 

Request a sample and discover the recent advances in Glioblastoma Treatment Drugs @ Glioblastoma Pipeline Report

 

In the Glioblastoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Glioblastoma clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Glioblastoma Overview

Glioblastoma Multiforme is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. Somatic evolution promotes the progression of cancer in which the genome of the cancer cell is being deviated from that of the healthy cell due the accumulation of mutations.

 

Find out more about Glioblastoma Therapeutics Assessment @ Glioblastoma Preclinical and Discovery Stage Products

 

Glioblastoma Emerging Drugs Profile

  • Enzastaurin: Denovo BioPharma
  • Tofacitinib: Pfizer
  • VT1021: Vigeo Therapeutics
  • Varlilumab: Celldex Therapeutics
  • Debio 0123: Debiopharm
  • PRT3645: Prelude Therapeutics

 

Glioblastoma Pipeline Therapeutics Assessment

There are approx. 195+ key companies which are developing the Glioblastoma therapies. The Glioblastoma companies which have their Glioblastoma drug candidates in the most advanced stage, i.e. phase III include, Denovo BioPharma.

 

Learn more about the emerging Glioblastoma Pipeline Therapies @ Glioblastoma Clinical Trials Assessment

 

Scope of the Glioblastoma Pipeline Report

  • Coverage- Global
  • Glioblastoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Glioblastoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Glioblastoma Companies- Denovo BioPharma, Pfizer, Vigeo Therapeutics, Celldex Therapeutics, Debiopharm, Prelude Therapeutics, AiVita Biomedical, Ascletis Pharma, Kintara Therapeutics, Bayer AG, Kazia Therapeutics, GlaxoSmithKline, Candel Therapeutics, Symphogen A/S, Sanofi, Oblato, Jiangsu Hengrui Medicine, BPGbio, Inc., Alaunos Therapeutics, Eli Lilly and Company, Actuate Therapeutics, Oncotelic Therapeutics, The Menarini Group, SonALAsense, Novartis, Allarity Therapeutics, PharmAbcine, I-Mab Biopharma Co. Ltd., Aadi Bioscience Inc., Matrix Biomed, Photonamic GmbH & Co. KG, Lixte, Black Diamond Therapeutics, Tmunity Therapeutics, SOM Biotech, Moleculin, Xynomic Pharmaceuticals, OncoSynergy, and others.
  • Glioblastoma Pipeline Therapies- PLX3397, Temozolomide, VXM01, Avelumab, Cilengitide, ACT001, and others.

 

Dive deep into rich insights for new drugs for Glioblastoma Treatment, Visit @ Glioblastoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Glioblastoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Glioblastoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Enzastaurin: Denovo BioPharma
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Varlilumab: Celldex Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. PRT3645: Prelude Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. ELC-401: Elicera Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Glioblastoma Key Companies
  21. Glioblastoma Key Products
  22. Glioblastoma- Unmet Needs
  23. Glioblastoma- Market Drivers and Barriers
  24. Glioblastoma- Future Perspectives and Conclusion
  25. Glioblastoma Analyst Views
  26. Glioblastoma Key Companies
  27. Appendix

 

For further information on the Glioblastoma Pipeline therapeutics, reach out to Glioblastoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking